Half of new US-approved drugs remain unavailable to Japanese patients
Nikkei Asia reports that many of the treatments have no development plans in Japan, citing regulatory and language barriers.
TLDR
Nikkei Asia reports that half of new US-approved drugs remain unavailable to Japanese patients. It says many treatments have no plans for development in Japan because of regulatory and language barriers.
Combined views
4.1K
2 Sources, first seen 7h ago
4 likes